Trial Profile
Rituximab Plus Lenalidomide or Rituximab Monotherapy for Untreated Patients With Follicular Lymphoma in Need of Therapy. A Randomized, Open-Label, Multicenter Phase II Trial.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Lenalidomide
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 12 Dec 2023 Results(n=154) presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 26 Jun 2023 Status changed from active, no longer recruiting to discontinued. It was decided by the trial team to stop the collection of follow up data in trial SAKK 35/10.
- 25 Apr 2023 This trial has been discontinued in Denmark (global end date: 2023-01-27), according to European Clinical Trials Database.